Lauren Green
Moncks Corner, SCNPI 1518744192
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.
Across 70 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$252
- Lilly USA, LLC$188
- Pfizer$174
- Amgen$102
- GSK$97
- Abbott$68
- plus $436 from 15 others
What the payments were for
- Food & beverage$1,318100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $252 |
| Lilly USA, LLC | 10 | $188 |
| Pfizer | 11 | $174 |
| Amgen | 5 | $102 |
| GSK | 6 | $97 |
| Abbott | 3 | $68 |
| Corcept Therapeutics | 3 | $62 |
| Boehringer Ingelheim | 2 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $38 |
| AbbVie | 2 | $37 |
| Bayer | 2 | $35 |
| Dexcom, Inc. | 1 | $32 |
| Astellas Pharma US Inc | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $22 |
| Renalytix AI, Inc. | 1 | $20 |
| Inari Medical, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Organon | 1 | $12 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 11 | $21,062 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $657 |
| Baclofen | 23 | $457 |
| Doxycycline Hyclate | 26 | $339 |
| Omeprazole | 18 | $314 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $313 |
| Atorvastatin Calcium | 21 | $306 |
| Losartan Potassium | 14 | $223 |
| Trazodone Hcl | 15 | $223 |
| Potassium Chloride | 15 | $214 |
| Fluticasone Propionate | 21 | $205 |
| Levothyroxine Sodium | 19 | $143 |
| Buspirone Hcl | 17 | $93 |
| Hydrochlorothiazide | 11 | $92 |
| Prednisone | 41 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $188 | $21,06211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.